Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;17(8):6356-6363.
doi: 10.21037/jtd-2025-705. Epub 2025 Aug 27.

The COURSE trial and beyond: rethinking chronic obstructive pulmonary disease exacerbation management with biologics

Fumihiro Kashizaki  1 , Hao Chen  1
Affiliations
Editorial

The COURSE trial and beyond: rethinking chronic obstructive pulmonary disease exacerbation management with biologics

Fumihiro Kashizaki et al. J Thorac Dis. .
No abstract available

Keywords: Tezepelumab; biologic; chronic obstructive pulmonary disease (COPD); exacerbation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-705/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. World Health Organization. Chronic obstructive pulmonary disease (COPD). Updated 6 November 2024. [Accessed April 1, 2025]. Available online: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pul...
    1. Global Initiative for Chronic Obstructive Lung Disease. GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2025 Report. [Accessed April 1, 2025]. Available online: https://goldcopd.org/2025-gold-report/
    1. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med 2024;390:2274-83. 10.1056/NEJMoa2401304 - DOI - PubMed
    1. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med 2023;389:205-14. 10.1056/NEJMoa2303951 - DOI - PubMed
    1. Konishi K, Takeuchi K, Hayakawa N, et al. Biomarkers Identifying the Effectiveness of Biologic Agents in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis biological agent. Journal of Clinical Question 2024;1:31-41.

LinkOut - more resources